How Evidence Quality Scores Impact HTA Assessment Success: The 2.9 Benchmark
Since 2020, assets with an average Evidence Quality score of 2.9 have sailed through HTA assessments more regularly than those at 2.7—simply because rigorous, reproducible studies earn payers’ confidence. That 0.2-point gap can mean the difference between swift coverage and costly delays.
That 0.2-point gap can mean the difference between swift coverage and costly delays.
Why Evidence Quality Matters in HTA Assessment
Evidence Quality & Robustness underpins every dimension of market-access risk. It captures whether your clinical data are:
- Methodologically sound: Randomized, controlled, blinded, and powered to detect meaningful differences.
- Complete and transparent: All primary and secondary endpoints reported, with minimal missing or immature data.
- Unbiased: Free from conflicts of interest, open-label pitfalls, or attrition imbalances.
- Reproducible: Confirmed by independent trials or real-world datasets.
Without independent scrutiny, internal teams systematically overestimate their HTA success rates. As a result, groupthink replaces objectivity – and market access strategies suffer.
Strong vs. Marginal Evidence Quality Profiles
Understanding where your asset falls on the evidence quality spectrum is critical for HTA readiness.
Strong Evidence (A++/A+/A)
Multiple high-quality trials, comprehensive endpoint data, and minimal bias translate to HTA bodies’ full trust. These assets achieve an average Evidence Quality score ≥2.9, leading to faster reimbursement decisions.
Marginal Evidence (B++ to C)
Scores ≤2.7 often reflect trial gaps or questionable methodology. These evidence profiles trigger conditional recommendations, requests for new studies, or outright rejections from payers.
The bottom line: Even a 0.1-point lift can reclassify your dossier from “uncertain” to “solid evidence.”
How to Improve Evidence Quality: Actionable Tips by Role
Market Access Teams
Build rigor into your pivotal trials from day one. Randomize, control, power appropriately, and pre-specify endpoints. Strong clinical trial design directly impacts your Evidence Quality score.
Investors & Acquirers
Vet evidence for bias risks before making investment decisions. Prioritize assets supported by peer-reviewed Phase III trials with transparent methodology.
Drug Developers
Publish interim and final results promptly to demonstrate transparency. In addition, augment RCTs with real-world evidence studies or meta-analyses to strengthen reproducibility.
Benchmark Your Competitive Edge
Our anonymized score distributions across 350+ assets reveal exactly where your evidence shines – and where it may leave payers wanting more.
Do you know how your product scores on Evidence Quality & Robustness?
Explore 350+ independent assessments in our online catalogue: https://mararating.com/mara-ratings-list
Follow MARA Rating for more independent HTA insights: linkedin.com/company/mara-rating-company
Related Topics: Market Access Risk Assessment | HTA Evidence Requirements | Clinical Trial Quality | Payer Evidence Standards | Reimbursement Strategy#MarketAccessRiskAssessment #HTAAssessment #EvidenceQuality #MARARating #MarketAccessBenchmark #PharmaInsights